Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
15 studies found for:    voreloxin
Show Display Options
Rank Status Study
1 Completed Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Condition: Acute Myeloid Leukemia
Intervention: Drug: voreloxin injection and cytarabine
2 Completed Study of Voreloxin in Older Patients With Untreated Acute Myeloid Leukemia
Conditions: Leukemia;   Acute Disease;   Acute Myeloid Leukemia;   Nonlymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: voreloxin
3 Completed Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Intervention: Drug: Voreloxin Injection
4 Active, not recruiting Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: vosaroxin;   Drug: Azacitidine
5 Active, not recruiting Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
Condition: Myelodysplastic Syndrome
Intervention: Drug: Vosaroxin
6 Completed Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
Conditions: Leukemia, Lymphocytic, Acute;   Leukemia, Nonlymphocytic, Acute;   Leukemia, Myeloid, Chronic;   Myelodysplastic Syndromes
Intervention: Drug: Vosaroxin
7 Active, not recruiting Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Condition: Leukemia
Interventions: Drug: Vosaroxin;   Drug: Decitabine
8 Recruiting Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Myeloid Sarcoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
Interventions: Drug: Cytarabine;   Drug: Vosaroxin
9 Completed
Has Results
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
Condition: Acute Myeloid Leukemia
Interventions: Drug: vosaroxin + cytarabine;   Drug: placebo + cytarabine
10 Suspended Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Vosaroxin and Cytarabine
11 Completed Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
Condition: Neoplasms
Intervention: Drug: SNS-595
12 Completed Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
Condition: Neoplasms
Intervention: Drug: SNS-595
13 Completed Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Conditions: Carcinoma, Small Cell;   Small Cell Lung Cancer
Intervention: Drug: SNS-595 Injection
14 Completed Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: SNS-595 Injection
15 Recruiting Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Idarubicin;   Drug: Daunorubicin;   Drug: HD Cytarabine;   Drug: Cyclosporine;   Drug: Methotrexate;   Drug: Mycophenolic acid (MPA);   Drug: vosaroxin;   Drug: ID cytarabine

Study has passed its completion date and status has not been verified in more than two years.